Drug Profile
Research programme: inflammatory disease therapeutics - AstraZeneca
Alternative Names: AZ 10397767; CXCR2/CCR2b antagonists - AstraZenecaLatest Information Update: 28 Feb 2011
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Pyrimidinones; Small molecules
- Mechanism of Action CCR2 receptor antagonists; Interleukin 8B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease; Psoriasis; Rheumatoid arthritis
Most Recent Events
- 28 Feb 2011 No development reported - Preclinical for Asthma in United Kingdom (PO)
- 28 Feb 2011 No development reported - Preclinical for Chronic obstructive pulmonary disease in United Kingdom (PO)
- 28 Feb 2011 No development reported - Preclinical for Psoriasis in United Kingdom (PO)